Thanks nuke, It was, in fact, a mono-therapy trial, I took it as NP+G, but it was NP after G. So, essentially it was a 2nd line trial. It seems that the previous treatment was only with Gem. They picked up patients whose cancers had progressed and started them on NP. I was looking for Phase 2 or Phase 3 NP+G pancreatic trials but not finding them.
Here are two Phase 1/2 trials that show front-line patients getting NP+G. One had a 12.3 month OS. Bavi should enhance these paired chemotherapies with its immo-therapeutical abilities. A really strong partnership for Peregrine would allow them to quickly get bavi moving through numerous trials and indications. Otherwise, I think an acquisition by a powerful pharma would be the better route to rapidly expand the clinical trials needed to get anti-PS fully developed in the least amount of time.
Nuke, I was fishing around a bit more looking through news coverage. The phase 3 NP+G pancreatic trial is still under wraps, but thestreet.com was "suggesting" a survival number of 8 months. They said: "Investors are likely to view a survival benefit of 8 months for Abraxane/gemcitabine compared to 6 months for gemcitabine alone as a very positive result."
News 
Market Data 
Discover 
AI
